Figure 3.

Expression profiles of zebrafish vegfaa, vegfr1 and vegfr2 genes. The graphs show data of the mRNA expression of (a) vegfaa, (b) vegfr1 and (c) vegfr2 from pooled 72-h post-fertilization (hpf) wild-type zebrafish larvae (n = 30) in six experimental groups: (1) control, (2) exposed to 5 mM CoCl₂; (3) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L bromocriptine; (4) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L cabergoline; (5) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L pergolide; and (6) exposed to a mixture of 5 mM CoCl₂ and 2.5 µM/L bevacizumab. Each group was covered by samples analyzed in triplicate in three separate experiments. Data in the figure represent the average of the three individual experiments. Gene expression values were normalized to housekeeping gene ef1-α; 5 mM CoCl₂ exposure resulted in significant upregulation of the expression of vegfaa in comparison to the control group (a). Co-treatment with 2.5 µM/L bromocriptine, 2.5 µM/L cabergoline, 2.5 µM/L pergolide and 2.5 µM/L bevacizumab resulted in a statistically significant decrease in the expression of previously up regulated vegfaa (a). The expression of vegfr1 and vegfr2 were not altered by both 5 mM CoCl₂ treatment and dopaminergic agonists’ co-treatment in comparison to the control (b). (One-way ANOVA, GraphPad Prism 5, *** p < 0.001; ** p < 0.01; * p < 0.05; ns: not statistically significant differences (p > 0.05)).